发明名称 |
Coated capsules and tablets of a fatty acid oil mixture |
摘要 |
Compositions comprising a fatty acid oil mixture and at least one free fatty acid in a coated capsule or a coated tablet form suitable for oral administration, and methods of use thereof, are disclosed. Further disclosed are preconcentrates comprising a fatty acid oil mixture, at least one surfactant, and optionally at least one free fatty acid, in a coated capsule or a coated tablet form, and methods of use thereof. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. |
申请公布号 |
US9370493(B2) |
申请公布日期 |
2016.06.21 |
申请号 |
US201013503465 |
申请日期 |
2010.10.22 |
申请人 |
Pronova Biopharma Norge AS |
发明人 |
Klaveness Jo Erik Johnsrud;Berge Gunnar;Hustvedt Svein Olaf;Olesen Preben Houlberg;Müllertz Anette |
分类号 |
A61K9/28;A61K9/48;C11C3/02;A61K31/202;A23L1/00;A23L1/30;A61K9/107;A61K31/557;A61K45/06 |
主分类号 |
A61K9/28 |
代理机构 |
Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P. |
代理人 |
Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P. |
主权项 |
1. A preconcentrate in a gelatin capsule or a tablet form comprising:
a fatty acid oil mixture comprising from about 45% to about 55% by weight, relative to the weight of the preconcentrate, wherein the fatty acid oil mixture comprises from about 80% to about 88% eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by weight of the fatty acid oil mixture, and the EPA and DHA are in ethyl ester form; and at least one free fatty acid comprising from about 10% to about 15% by weight, relative to the weight of the preconcentrate, of the at least one free fatty acid, wherein the at least one free fatty acid comprises from about 80% to about 88% EPA and DHA, by weight of the at least one free fatty acid, and the EPA and DHA are in free fatty acid form; and at least one nonionic surfactant comprising from about 15% to about 35% by weight, relative to the weight of the preconcentrate, wherein the at least one nonionic surfactant is chosen from comprises polysorbate 20;wherein the gelatin capsule or the tablet comprises at least one coating; andfurther wherein the preconcentrate, the gelatin capsule, and the at least one coating do not comprise an additional active pharmaceutical ingredient other than the fatty acid oil mixture. |
地址 |
Lysaker NO |